Inhibrx Biosciences (INBX) Amortization of Deferred Charges (2023 - 2025)

Inhibrx Biosciences (INBX) has reported Amortization of Deferred Charges for 3 consecutive years, with $642000.0 the latest figure, recorded in Q4 2025.

• In Q4 2025, Amortization of Deferred Charges changed N/A year-over-year to $642000.0; the TTM figure through Dec 2025 stood at $2.4 million (up 18.11% YoY), while the FY2025 annual figure was $2.4 million, up 18.11% from the prior year.
• Amortization of Deferred Charges rose to $642000.0 in Q4 2025 per INBX's latest filing, from $638000.0 in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $1.2 million in Q4 2023 and bottomed at $533000.0 in Q1 2025.
• Historically, Amortization of Deferred Charges has averaged $873750.0 across 3 years, with a median of $732500.0 in 2024.
• On a YoY basis, Amortization of Deferred Charges climbed as much as 23.94% in 2025 and fell as far as 57.09% in 2025.
• Inhibrx Biosciences' Amortization of Deferred Charges stood at $1.2 million in 2023, then tumbled by 34.0% to $823000.0 in 2024, then fell by 21.99% to $642000.0 in 2025.
• Business Quant data shows INBX's Amortization of Deferred Charges at $642000.0 in Q4 2025, $638000.0 in Q3 2025, and $626000.0 in Q2 2025.